|
BRPI0718029A2
(pt)
*
|
2006-11-06 |
2013-11-26 |
Supergen Inc |
Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
|
|
AR067326A1
(es)
*
|
2007-05-11 |
2009-10-07 |
Novartis Ag |
Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
|
|
US8431608B2
(en)
|
2007-08-17 |
2013-04-30 |
Icagen Inc. |
Heterocycles as potassium channel modulators
|
|
AU2008289101A1
(en)
*
|
2007-08-17 |
2009-02-26 |
Icagen, Inc. |
Heterocycles as potassium channel modulators
|
|
PE20091468A1
(es)
|
2008-02-28 |
2009-10-22 |
Novartis Ag |
DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
|
|
EP2277881A4
(en)
*
|
2008-04-18 |
2011-09-07 |
Shionogi & Co |
HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
|
|
EP2279262B1
(en)
*
|
2008-04-25 |
2013-12-25 |
PamGene B.V. |
Measurement of protein kinase activity in cerebrospinal fluid for diagnosis of neurological and psychiatric disorders
|
|
WO2009140128A2
(en)
*
|
2008-05-13 |
2009-11-19 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
PT2350075E
(pt)
|
2008-09-22 |
2014-06-09 |
Array Biopharma Inc |
Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
|
|
TWI491610B
(zh)
|
2008-10-09 |
2015-07-11 |
必治妥美雅史谷比公司 |
作為激酶抑制劑之咪唑并嗒腈
|
|
AR074052A1
(es)
|
2008-10-22 |
2010-12-22 |
Array Biopharma Inc |
Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
|
|
WO2010062829A1
(en)
*
|
2008-11-28 |
2010-06-03 |
Lexicon Pharmaceuticals, Inc. |
Tryptophan hydroxylase inhibitors for treating osteoporosis
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
US8815918B2
(en)
|
2009-04-02 |
2014-08-26 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives
|
|
EP2243481A1
(en)
*
|
2009-04-24 |
2010-10-27 |
PamGene B.V. |
Irak kinase family as novel drug target for Alzheimer
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
PH12012500778A1
(en)
|
2009-10-30 |
2012-11-26 |
Janssen Pharmaceutica Nv |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
|
|
AR080754A1
(es)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
|
|
JP5583845B2
(ja)
|
2010-04-28 |
2014-09-03 |
ブリストル−マイヤーズ スクイブ カンパニー |
イミダゾピリダジニル化合物および癌に対するそれらの使用
|
|
NZ604708A
(en)
|
2010-05-20 |
2015-05-29 |
Array Biopharma Inc |
Macrocyclic compounds as trk kinase inhibitors
|
|
US9266880B2
(en)
|
2010-11-12 |
2016-02-23 |
Bristol-Myers Squibb Company |
Substituted azaindazole compounds
|
|
KR20180099933A
(ko)
|
2010-11-19 |
2018-09-05 |
리간드 파마슈티칼스 인코포레이티드 |
복소환 아민 및 이의 용도
|
|
EP2463289A1
(en)
*
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
|
CA2836203A1
(en)
|
2011-05-17 |
2012-11-22 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
|
|
WO2012163942A1
(en)
|
2011-06-01 |
2012-12-06 |
Bayer Intellectual Property Gmbh |
Substituted aminoimidazopyridazines
|
|
US9284319B2
(en)
|
2011-06-22 |
2016-03-15 |
Bayer Intellectual Property Gmbh |
Heterocyclyl aminoimidazopyridazines
|
|
BR112013033375B1
(pt)
|
2011-06-27 |
2022-05-10 |
Janssen Pharmaceutica N.V |
Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
UA117092C2
(uk)
*
|
2011-09-06 |
2018-06-25 |
Байєр Інтеллектуал Проперті Гмбх |
Амінозаміщені імідазопіридазини
|
|
WO2013041634A1
(en)
|
2011-09-23 |
2013-03-28 |
Bayer Intellectual Property Gmbh |
Substituted imidazopyridazines
|
|
US8969586B2
(en)
|
2011-09-27 |
2015-03-03 |
Bristol-Myers Squibb Company |
Substituted bicyclic heteroaryl compounds
|
|
WO2013066729A1
(en)
*
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
|
JP6147761B2
(ja)
*
|
2011-12-12 |
2017-06-14 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
アミノ置換イミダゾピリダジン
|
|
EP2802576B1
(en)
*
|
2012-01-13 |
2018-06-27 |
Bristol-Myers Squibb Company |
Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
|
|
RU2014140739A
(ru)
*
|
2012-03-09 |
2016-04-27 |
Лексикон Фармасьютикалз, Инк. |
Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
|
|
ES2663609T3
(es)
|
2012-03-29 |
2018-04-16 |
Bayer Intellectual Property Gmbh |
Imidazopiridazinas amino-sustituidas
|
|
JP6173430B2
(ja)
*
|
2012-04-04 |
2017-08-02 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
アミノ置換イミダゾピリダジン
|
|
HK1206250A1
(en)
|
2012-06-26 |
2016-01-08 |
Janssen Pharmaceutica Nv |
Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders
|
|
WO2014009305A1
(en)
|
2012-07-09 |
2014-01-16 |
Janssen Pharmaceutica Nv |
Inhibitors of phosphodiesterase 10 enzyme
|
|
PL400213A1
(pl)
|
2012-08-01 |
2014-02-03 |
Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia |
Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
|
|
EP2914296B2
(en)
|
2012-11-01 |
2021-09-29 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
CN105164124B
(zh)
|
2012-11-19 |
2017-03-15 |
诺华股份有限公司 |
用于治疗寄生虫疾病的化合物和组合物
|
|
ES2646916T3
(es)
|
2012-11-19 |
2017-12-18 |
Bayer Pharma Aktiengesellschaft |
Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa
|
|
US9745304B2
(en)
|
2013-01-30 |
2017-08-29 |
Bayer Pharma Aktiengesellschaft |
Amidoimidazopyridazines as MKNK-1 kinase inhibitors
|
|
JP2016509036A
(ja)
*
|
2013-02-20 |
2016-03-24 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
Ｍｋｎｋ１阻害剤としての置換イミダゾ［１，２−ｂ］ピリダジン
|
|
JP2016510764A
(ja)
|
2013-03-07 |
2016-04-11 |
カリフィア バイオ, インク.Califia Bio, Inc. |
混合系キナーゼ阻害剤および治療法
|
|
US20160024051A1
(en)
|
2013-03-15 |
2016-01-28 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
SG11201509842SA
(en)
|
2013-05-30 |
2015-12-30 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
AR097543A1
(es)
*
|
2013-09-06 |
2016-03-23 |
Lexicon Pharmaceuticals Inc |
COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
|
|
EP3080131B1
(en)
*
|
2013-12-10 |
2018-10-10 |
Bristol-Myers Squibb Company |
Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
|
|
JP2017503809A
(ja)
*
|
2014-01-09 |
2017-02-02 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
アミド置換イミダゾピリダジン
|
|
SG11201605408RA
(en)
|
2014-01-10 |
2016-07-28 |
Aurigene Discovery Tech Ltd |
Indazole compounds as irak4 inhibitors
|
|
FI3805233T3
(fi)
|
2014-01-13 |
2024-04-17 |
Aurigene Oncology Ltd |
N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
|
|
US9969749B2
(en)
|
2014-09-30 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
EP3200790B1
(en)
|
2014-09-30 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Inhibitors of irak4 activity
|
|
US9926330B2
(en)
|
2014-09-30 |
2018-03-27 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
US9932350B2
(en)
|
2014-09-30 |
2018-04-03 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
HUE061448T2
(hu)
|
2014-11-16 |
2023-07-28 |
Array Biopharma Inc |
(S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
|
|
MA41174B1
(fr)
|
2014-12-19 |
2019-09-30 |
Janssen Pharmaceutica Nv |
Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
|
|
AU2015366202B2
(en)
|
2014-12-19 |
2020-01-02 |
Janssen Pharmaceutica Nv |
Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors
|
|
CN104592121A
(zh)
*
|
2015-02-13 |
2015-05-06 |
佛山市赛维斯医药科技有限公司 |
含酰肼和硝基苯类结构的化合物、其制备方法及用途
|
|
US10807983B2
(en)
|
2015-03-16 |
2020-10-20 |
Ligand Pharmaceuticals, Inc. |
Imidazo-fused heterocycles and uses thereof
|
|
ES2822956T3
(es)
*
|
2015-06-24 |
2021-05-05 |
Bristol Myers Squibb Co |
Compuestos de aminopiridina sustituidos con heteroarilo
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
CN108697708A
(zh)
|
2015-10-26 |
2018-10-23 |
洛克索肿瘤学股份有限公司 |
Trk抑制剂抗性癌症中的点突变以及与此相关的方法
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
ES2987474T3
(es)
|
2016-04-04 |
2024-11-15 |
Loxo Oncology Inc |
Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
|
|
ES2836222T3
(es)
|
2016-05-18 |
2021-06-24 |
Loxo Oncology Inc |
Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
|
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
|
JP7117293B2
(ja)
|
2016-09-16 |
2022-08-12 |
ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） |
Ｔｒａｆ６阻害剤
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
US11547696B2
(en)
|
2016-10-28 |
2023-01-10 |
Children's Hospital Medical Center |
Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
DK3600270T3
(da)
|
2017-03-31 |
2023-07-10 |
Aurigene Oncology Ltd |
Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
|
|
EP3642201A1
(en)
*
|
2017-06-21 |
2020-04-29 |
H. Hoffnabb-La Roche Ag |
Isoindolinone derivatives as irak4 modulators
|
|
CA3079628A1
(en)
|
2017-10-31 |
2019-05-09 |
Curis, Inc. |
Compounds and compositions for treating hematological disorders
|
|
KR20200116481A
(ko)
*
|
2018-01-29 |
2020-10-12 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
CN111226956B
(zh)
*
|
2019-11-26 |
2021-10-26 |
贵州医科大学 |
3,6-二取代咪唑[1,2-b]哒嗪类衍生物在制备抑制植物病原真菌杀菌剂中的应用
|
|
EP4107158A1
(en)
|
2020-02-19 |
2022-12-28 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
CA3176337A1
(en)
*
|
2020-04-21 |
2021-10-28 |
Peter King |
Rna-binding protein multimerization inhibitors and methods of use thereof
|
|
US12605387B2
(en)
|
2020-07-24 |
2026-04-21 |
Secura Bio, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
|
CN114409656B
(zh)
*
|
2021-02-08 |
2022-09-23 |
杭州邦顺制药有限公司 |
Pim激酶抑制剂
|
|
KR20240004476A
(ko)
|
2021-04-08 |
2024-01-11 |
쿠리스 인코퍼레이션 |
암 치료를 위한 병용 요법
|
|
FI4367118T3
(fi)
|
2021-08-18 |
2025-04-09 |
Nurix Therapeutics Inc |
Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
|